Fluorine-18-labelled maleimide compounds of general formula (I): ##STR00001## in which: m represents an integer from 0 to 10; n represents an integer from 1 to 10; Y represents a group selected from optionally substituted monocyclic or bicyclic heterocyclic groups; X represents a radical of formula: (U).sub.a--((CR.sub.1R.sub.2).sub.b--(V).sub.c).sub.d--((CR.sub.3R.sub.4)- .sub.e--(W).sub.f).sub.g-- in which: a, b, c, d, e, f and g represent each independently an integer from 0 to 10; U, V and W represent each independently --NR.sub.1--, --O--, --S--, ##STR00002## ethynyl, --CR.sub.1.dbd.CR.sub.2--, --(C.dbd.O)--, --(C.dbd.S)--, --C(.dbd.NR.sub.1)--, --C(.dbd.O)O--, --(C.dbd.S)S--, --C(.dbd.NR.sub.1)NR.sub.2--, --CR.sub.1R.sub.2--, --CR.sub.1OR.sub.2-- or --CR.sub.1NR.sub.2R.sub.3--. Process for preparing these compounds; their use for labelling macromolecules, and complexes of these compounds with a macromolecule. Detection and analysis kit, or diagnosis kit, comprising the said complexes. Use of the complexes in a medical imaging process such as positron emission tomography (PET).
Claims The invention claimed is: 1. A compound according to formula (I): ##STR00026## wherein m represents an integer from 0 to 10; n represents an integer from 1 to 10; Y represents a monocyclic or bicyclic heterocyclic group selected from the group consisting of imidazolyl, pyrazolyl, benzimidazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl and purinyl, wherein Y may optionally be substituted with one or more substituents selected from the group consisting of hydrogen, halogen, phenyl, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, aryloxy, amino, mono- or di(C.sub.1-C.sub.6 alkyl)amino, mono- or di(aryl)amino, thio, C.sub.1-C.sub.6 alkylthio, arylthio, formyl, C.sub.1-C.sub.6 alkyl-carbonyl, arylcarbonyl, carbonyl, C.sub.1-C.sub.6 alkoxy-carbonyl, aryloxycarbonyl, C.sub.1-C.sub.6 alkylamino-carbonyl, arylaminocarbonyl and trifluoromethyl; and X represents a radical of the following formula: (U).sub.a--((CR.sub.1R.sub.2).sub.b--(V).sub.c).sub.d--((CR.sub.3R.sub.4- ).sub.e--(W).sub.f).sub.g-- wherein a, b, c, d, e, f and g each independently represent an integer from 0 to 10; and U, V and W each independently represent --NR.sub.1--, --O--, --S--, --N(--O)--, ethynyl, --CR.sub.1.dbd.CR.sub.2--, --(C.dbd.O)--, --(C.dbd.S)--, --C(.dbd.NR.sub.1)--, --C(.dbd.O)O--, --(C.dbd.S)S--, --C(.dbd.NR.sub.1)NR.sub.2--, --CR.sub.1R.sub.2--, --CR.sub.1OR.sub.2-- or --CR.sub.1NR.sub.2R.sub.3--, wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each independently selected from the group consisting of hydrogen, halogen, phenyl, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, aryloxy, amino, mono- or di(C.sub.1-C.sub.6 alkyl)amino, mono- or di(aryl)amino, thio, C.sub.1-C.sub.6 alkylthio, arylthio, formyl, C.sub.1-C.sub.6 alkyl-carbonyl, arylcarbonyl, carbonyl, C.sub.1-C.sub.6 alkoxy-carbonyl, aryloxycarbonyl, C.sub.1-C.sub.6 alkylamino-carbonyl, arylaminocarbonyl and trifluoromethyl. 2. The compound according to claim 1, wherein n is 1 and Y is a 3-pyridinyl group. 3. The compound according to claim 2, wherein the compound is represented by formula (II): ##STR00027## wherein p represents an integer from 1 to 10. 4. The compound according to claim 3, wherein the compound is selected from the group consisting of: 1-[2-(2-[.sup.18F]fluoropyridin-3-yloxy)ethyl]-pyrrole-2,5-dione; 1-[4-(2-[.sup.18F]fluoropyridin-3-yloxy)butyl]-pyrrole-2,5-dione; 1-[5-(2-[.sup.18F]fluoropyridin-3-yloxy)pentyl]-pyrrole-2,5-dione; 1-[6-(2-[.sup.18F]fluoropyridin-3-yloxy)hexyl]-pyrrole-2,5-dione; 1-[(2-[.sup.18F]fluoropyridin-3-yloxy)methyl]-pyrrole-2,5-dione; and 1-[3-(2-[.sup.18F]fluoropyridin-3-yloxy)propyl]-pyrrole-2,5-dione. 5. The compound according to claim 2, wherein the compound is represented by formula (III): ##STR00028## wherein q and r each independently represent an integer from 0 to 10. 6. The compound according to claim 5, wherein the compound is selected from the group consisting of: 1-{4-[2-(2-[.sup.18F]fluoropyridin-3-yloxy)-ethyl]phenyl}pyrrole-2,5-dion- e; 1-[4-(2-[.sup.18F]fluoropyridin-3-yloxymethyl)-phenyl]pyrrole-2,5-dione- ; and 1-[4-(2-[.sup.18F]fluoropyridin-3-yloxymethyl)-benzyl]pyrrole-2,5-di- one. 7. The compound according to claim 2, wherein the compound is represented by formula (IV): ##STR00029## wherein s represents an integer from 1 to 10. 8. The compound according to claim 7, wherein the compound is 1-[3-(6-[.sup.18F]fluoropyridin-3-yl)propyl]-pyrrole-2,5-dione. 9. The compound according to claim 2, wherein the compound is represented by formula (V): ##STR00030## wherein t represents an integer from 0 to 10; and T is a --CH.dbd.CH-- group or a --C.ident.C-- group. 10. The compound according to claim 9, wherein the compound is selected from the group consisting of: 1-[3-(6-[.sup.18F]fluoropyridin-3-yl)allyl]-pyrrole-2,5-dione; and 1-[3-(6-[.sup.18F]fluoropyridin-3-yl)prop-2-ynyl]pyrrole-2,5-dione. 11. A kit comprising a macromolecule and the compound according to claim 1. 12. The kit according to claim 11, wherein the kit is a detection and analysis kit for medical imaging. 13. The kit according to claim 11, wherein the kit is a diagnosis kit. 14. The kit according to claim 11, wherein the macromolecule is a biological macromolecule. 15. The kit according to claim 11, wherein the macromolecule is a biological macromolecule selected from the group consisting of an oligonucleotide, a protein, an antibody and a peptide. 16. The kit according to claim 11, wherein the macromolecule is a macromolecule for recognition of a specific site that exhibits target molecules associated with a particular disease. 17. The kit according to claim 11, wherein the macromolecule is a macromolecule for recognition of a specific site that is selected from the group consisting of apoptosis sites, necrosis sites or tumor sites. 18. A process for preparing the compound according to claim 1, wherein the process comprises: contacting a precursor compound according to formula (Ia): ##STR00031## wherein PR.sub.1 and PR.sub.2 each independently represent: a hydrogen or a protective group, with the proviso that PR.sub.1 and PR.sub.2 are not both a hydrogen; or PR.sub.1 and PR.sub.2, together with the nitrogen atom, form a cyclic protective group; Gp represents a leaving group capable of being replaced by a fluorine-18 atom; m represents an integer from 0 to 10; n represents an integer from 1 to 10; Y represents a monocyclic or bicyclic heterocyclic group selected from the group consisting of imidazolyl, pyrazolyl, benzimidazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl and purinyl, wherein Y may optionally be substituted with one or more substituents selected from the group consisting of hydrogen, halogen, phenyl, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, aryloxy, amino, mono- or di(C.sub.1-C.sub.6 alkyl)amino, mono- or di(aryl)amino, thio, C.sub.1-C.sub.6 alkylthio, arylthio, formyl, C.sub.1-C.sub.6 alkyl-carbonyl, arylcarbonyl, carbonyl, C.sub.1-C.sub.6 alkoxy-carbonyl, aryloxycarbonyl, C.sub.1-C.sub.6 alkylamino-carbonyl, arylaminocarbonyl and trifluoromethyl; and X represents a radical of the following formula: (U).sub.a--((CR.sub.1R.sub.2).sub.b--(V).sub.c).sub.d--((CR.sub.3R.sub.4- ).sub.e--(W).sub.f).sub.g-- wherein a, b, c, d, e, f and g each independently represent an integer from 0 to 10; and U, V and W each independently represent --NR.sub.1--, --O--, --S--, --N(--O)--, ethynyl, --CR.sub.1.dbd.CR.sub.2--, --(C.dbd.O)--, --(C.dbd.S)--, --C(.dbd.NR.sub.1)--, --C(.dbd.O)O--, --(C.dbd.S)S--, --C(.dbd.NR.sub.1)NR.sub.2--, --CR.sub.1R.sub.2--, --CR.sub.1OR.sub.2-- or --CR.sub.1NR.sub.2R.sub.3--, wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each independently selected from the group consisting of hydrogen, halogen, phenyl, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, aryloxy, amino, mono- or di(C.sub.1-C.sub.6 alkyl)amino, mono- or di(aryl)amino, thio, C.sub.1-C.sub.6 alkylthio, arylthio, formyl, C.sub.1-C.sub.6 alkyl-carbonyl, arylcarbonyl, carbonyl, C.sub.1-C.sub.6 alkoxy-carbonyl, aryloxycarbonyl, C.sub.1-C.sub.6 alkylamino-carbonyl, arylaminocarbonyl and trifluoromethyl. with a source of [.sup.18F]-labeled fluoride anions (F) to provide a compound according to formula (Ib): ##STR00032## removing the protective group(s) PR.sub.1 and/or PR.sub.2 from the compound according to formula (Ib) to provide a compound according to formula (Ic): H.sub.2N--(X).sub.m--(Y).sub.n--.sup.18F (Ic); and reacting the compound according to formula (Ic) with a reactant capable of providing a maleimido group from an amino group, to yield the compound according to claim 1. 19. The process according to claim 18, wherein the protective group(s) PR.sub.1 and/or PR.sub.2 is/are selected from the group consisting of tert-butoxycarbonyl (BOC) and fluorenylmethoxycarbonyl (FMOC). 20. The process according to claim 18, wherein the protective groups PR.sub.1 and PR.sub.2, together with the nitrogen atom, form a phthalamido protective group. 21. The process according to claim 18, wherein Gp is selected from the group consisting of a halogen, a mesyl group, a tosyl group, a triflate group, a nitro group and an ammonium salt. 22. The process according to claim 21, wherein Gp is an ammonium salt and the ammonium salt is trimethylammonium trifluoromethanesulphonate. 23. The process according to claim 18, wherein the source of [18F]-labeled fluoride anions (F) comprises the fluoride anions (F) and a counterion. 24. The process according to claim 23, wherein the counterion is a cation selected from the group consisting of rubidium, tetrabutylammonium, potassium, sodium and lithium. 25. The process according to claim 23, wherein the counterion is a cation selected from the group consisting of potassium, sodium and lithium, and the cation is stabilized by a cryptand or a crown ether. 26. The process according to claim 18, wherein said removing is carried out by deprotecting the compound according to formula (Ib) with trifluoroacetic acid (TFA) in a solvent for a period of 1-5 minutes to provide the compound according to formula (Ic). 27. The process according to claim 26, wherein the solvent is dichloromethane. 28. The process according to claim 18, wherein the reactant capable of providing a maleimido group from an amino group is selected from the group consisting of N-methoxycarbonylmaleimide and succinimide. 29. The process according to claim 18, wherein said reacting is carried out in a solvent with heating at a temperature of 100-200.degree. C. for a period of 1-20 minutes. 30. The process according to claim 29, wherein the solvent is xylene or tetrahydrofuran. 31. The process according to claim 18, wherein said reacting is carried out in a two-phase mixture at ambient temperature for a period of 3-15 minutes. 32. The process according to claim 31, wherein the two-phase mixture comprises dioxane and aqueous sodium bicarbonate. 33. The process according to claim 18, wherein the precursor compound according to formula (Ia) corresponds to a compound according to formula (IIa): ##STR00033## wherein p represents an integer from 1 to 10. 34. The process according to claim 18, wherein the precursor compound according to formula (Ia) corresponds to a compound according to formula (IIb): ##STR00034## wherein p represents an integer from 1 to 10. 35. The process according to claim 18, wherein the precursor compound according to formula (Ia) corresponds to a compound according to formula (IIIa): ##STR00035## wherein q and r each independently represent an integer from 0 to 10. 36. The process according to claim 18, wherein the precursor compound according to formula (Ia) corresponds to a compound according to formula (IIIb): ##STR00036## wherein q and r each independently represent an integer from 0 to 10. 37. The process according to claim 18, wherein the precursor compound according to formula (Ia) corresponds to a compound according to formula (IVa): ##STR00037## wherein s represents an integer from 1 to 10. 38. The process according to claim 18, wherein the precursor compound according to formula (Ia) corresponds to a compound according to formula (IVb): ##STR00038## wherein s represents an integer from 1 to 10. 39. The process according to claim 18, wherein the precursor compound according to formula (Ia) corresponds to a compound according to formula (Va): ##STR00039## wherein t represents an integer from 0 to 10; and T is a --CH.dbd.CH-- group or a --C.ident.C-- group. 40. The process according to claim 18, wherein the precursor compound according to formula (Ia) corresponds to a compound according to formula (Vb): ##STR00040## wherein t represents an integer from 0 to 10; and T is a --CH.dbd.CH-- group or a --C.ident.C-- group. 41. A method of labeling a macromolecule comprising coupling the compound according to claim 1 to the macromolecule. 42. The method according to claim 41, wherein the macromolecule is a biological macromolecule. 43. The method according to claim 41, wherein the macromolecule is a biological macromolecule selected from the group consisting of an oligonucleotide, a protein, an antibody and a peptide. 44. The method according to claim 41, wherein the macromolecule is a macromolecule for recognition of a specific site that exhibits target molecules associated with a particular disease. 45. The method according to claim 41, wherein the macromolecule is a macromolecule for recognition of a specific site that is selected from the group consisting of apoptosis sites, necrosis sites or tumor sites. 